Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Protecting the US from bio-threats: a public-private approach

Mid-way through 2012 and it’s easy to feel that the United States (US) Government has stopped taking bio-security seriously. The Obama administration’s reluctance to deal with the issue has received widespread criticism but, as Dr Nicola Davies discovers, the establishment of three dedicated new centres alongside pharma giants Emergent Biosolutions, GSK and Novartis could signal a more practical approach to active bio-defence.

Go Top